What do systematic reviews say?

Extracorporeal photopheresis vs PUVA

The review found no eligible studies for this question.

• Interventions for mycosis fungoides 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bexarotene + PUVA vs PUVA

The review found no eligible studies for this question.

• Interventions for mycosis fungoides 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cognitive training vs control intervention

• Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 147 participants
  Low

Long‐term red cell transfusion vs usual care

The review found no eligible studies for this question.

• Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Transfusions continued vs transfusions halted

The review found no eligible studies for this question.

• Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs RBC transfusion

The review found no eligible studies for this question.

• Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs RBC transfusion

The review found no eligible studies for this question.

• Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Intervention not reported

• Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Serlopitant 0.25 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Serlopitant 5 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Serlopitant 1 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 128 participants
  Very low

Amifostine vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sodium thiosulfate vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found